Search

everythinglearnresearchcommunity

for

Search:↓

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Lysocellin helps stop cell damage from etoposide and may prevent hair loss.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

MK-5108 is safe and shows potential against tumors, especially alone.

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

A new genetic region, 17q21.31, is linked to higher ovarian cancer risk.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Pexidartinib often causes liver issues and fatigue, especially in women.

PPARγ signaling modulation can protect hair follicle stem cells from chemotherapy-induced damage.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

XMU-MP-1 stops cell growth in a human mini-organ and reduces the effectiveness of the chemotherapy drug paclitaxel.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.

Bempikibart may help regrow hair in people with alopecia areata.